Emergency Use of Tocilizumab in Moderate and Severe COVID-19 Patients over the Prevaccination Stage during the Pandemic in Mexico
Introduction. COVID-19 has been associated with the overactivation of the immune system; interleukin-6 (IL-6) seems to have a key role, which made its moderation to be proposed as a therapeutic blank. Tocilizumab has been used as part of treatments to modulate the immune response to infections cause...
Saved in:
| Main Authors: | Yessica Bernal Luna, Alejandro Esquivel Loza, José de Jesús Garduño García |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Advances in Virology |
| Online Access: | http://dx.doi.org/10.1155/2022/6880405 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The use of different formulations of tocilizumab in the treatment of patients with moderate to severe COVID-19
by: E. I. Veselova, et al.
Published: (2021-02-01) -
Varicella Zoster Virus Infections in Canadian Children in the Prevaccine Era: A Hospital-Based Study
by: Susan Kuhn, et al.
Published: (1997-01-01) -
The Importance of the Timing of Tocilizumab Administration in Moderate to Severely Ill COVID-19: Single Centered Experience Case series
by: Eric Daniel Tenda, et al.
Published: (2021-10-01) -
Efficacy of Tocilizumab in Patients with a Moderate and Severe COVID-19: A Retrospective Single Center Cohort Study
by: Sibel BOLUKÇU, et al.
Published: (2021-01-01) -
Risk factors for SARS-CoV-2 infection in Jordan: A cross-sectional study in the prevaccination period
by: Ahmad Ali Qaied Al-Mharmah, et al.
Published: (2024-09-01)